A Real Heartbreak for Celladon
Celladon announced negative results in clinical trial and shares plunged 80% Monday morning.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
On its website, Celladon Corp. (NASDAQ: CLDN) writes “Hope to Heart Patients.” Not to sound morbid, but the company appears to have lost at least some hope – in terms of dollars – when it announced negative results in its Cupid2 trial of Mydicar for treatment of advanced heart failure.
This announcement was followed by a near cataclysmic 80% drop in its stock price.
As for the study, Cupid2 is a Phase 2b trial evaluating a single intracoronary infusion of the cardiovascular gene therapy agent Mydicar. In the study, there were 250 adult patients who had stable New York Heart Association class II to IV ischemic or non-ischemic heart failure despite optimal therapy, reduced left ventricular ejection fraction and a high risk for recurrent heart-failure hospitalizations.
The study enrolled only patients with heart failure with reduced ejection fraction. The statistical analysis for the primary endpoint was performed on the modified intent to treat population, which comprised all patients who, after randomization, underwent cardiac catheterization and drug or placebo administration.
ALSO READ: 4 Biotech and Pharma Stocks Projected to Rise 50% to 100%
Krisztina Zsebo, Ph.D., CEO of Celladon commented on the trial:
We are surprised and very disappointed that MYDICAR failed to meet the endpoints in the CUPID2 trial, and we are rigorously analyzing the data in an attempt to better understand the observed outcome. We would like to express our sincere gratitude to our investigators and patients who participated in the study. At the same time we are evaluating our other programs in order to determine the best path forward to maximize shareholder value.
Prior to the announcement, a couple analysts had relatively positive outlooks for Celladon:
- BMO Capital markets initiated coverage with a Market Perform rating with a $15 price target.
- H.C. Wainright initiated coverage with a Buy rating and $31 price target.
Following the announcement a couple other analysts had something to say too:
- Wedbush downgraded Celladon to a Neutral rating and lowered its price target to $3 from $29.
- Roth Capital downgraded the company to a Neutral rating.
Shares of Celladon were down about 80% at $2.80 Monday morning, in a 52-week trading range of $2.76 to $28.25. The stock has a consensus analyst price target of $32.17.
ALSO READ: 5 Biotechs Not Keeping Up With the Hot Sector in 2015
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
